Blackstone Life Sciences

Blackstone Life Sciences operates as a dedicated investment group within Blackstone's private equity division. It was formed following the 2018 acquisition of Clarus, a life sciences investment firm, and integrates Clarus's team and investment approach into Blackstone's broader platform. Nicholas Galakatos, who co-founded Clarus, leads the group as Global Head. The structure allows the team to leverage Blackstone's institutional resources while maintaining a specialized focus on healthcare.

The group deploys capital across three primary strategies: royalty monetizations (acquiring revenue streams from approved drugs), structured credit secured by healthcare assets, and control or significant minority equity investments in commercial-stage companies. The equity strategy targets biopharma, medical devices, and healthcare technology businesses that have already achieved regulatory milestones or are generating revenue, rather than early-stage discovery bets.

No. The group explicitly avoids pre-clinical and Phase I venture capital. Its model targets products and companies that have cleared significant regulatory or clinical validation, providing growth capital for late-stage trials, commercialization, or market expansion. This risk posture aligns with Blackstone's broader preference for cash-flow-oriented assets.

The group sources royalty investments directly from biopharma companies, academic institutions, and inventors seeking to monetize future drug revenue streams without giving up equity. It also partners with companies to provide non-dilutive financing secured by royalty interests. Blackstone Life Sciences' ability to write checks exceeding $1 billion gives it an advantage in large, complex royalty transactions that smaller dedicated funds cannot underwrite.

In February 2025, Blackstone Life Sciences partnered with the UK government to launch a £200 million fund targeting UK-based biotech and medtech companies. The vehicle is capitalized with UK government backing and managed by Blackstone Life Sciences, combining public policy objectives with the group's commercial investment discipline. This represents a distinctive public-private collaboration model within the unit's broader strategy.